

Contents

Part I General ICU Topics

1 Evidence Based Critical Care	3
References.....	6
2 “Less Is More”: The New Paradigm in Critical Care	7
References.....	8
3 “Classic” Papers.....	13
4 Critical Care Medicine 101	19
Factors to Consider When a Patient is Admitted to the ICU.....	20
Initial “Generic” Treatment Orders.....	20
Reference	21
5 House Officers Guidelines 1: Housekeeping.....	23
Admission History and Physical Examination	23
Daily Examination	24
General.....	24
Vital Signs (24 h Min and Max and Current)	24
Additional Observations	24
The Ventilator.....	25
Heart.....	25
Chest	25
Abdomen.....	25
CNS.....	26
Importance of the Daily Neurological Examination.....	26
Laboratory Tests.....	26
Imaging	27
Presenting on Daily Rounds.....	27
New Admissions	27

Follow Up Patients	28
Clinical Pearls	28
References	28
6 House Officers Guidelines 2: Procedures	29
Murphy's Laws of Procedures	29
Central Venous Access	30
Subclavian Vein Catheterization	31
Internal Jugular Vein Catheterization	32
Femoral Vein Catheterization	33
Complications of Central Venous Access	34
Arterial Catheters	34
Naso/Oro Gastric Tubes	35
Feeding Tubes	36
Thoracentesis and Paracentesis	36
Clinical Pearls	37
References	37
7 Admission-Discharge Criteria	39
ICU Admission Criteria	39
Prioritization of Potential ICU Admissions	40
Priority 1	40
Priority 2	40
Priority 3	40
Priority 4	41
Transfer from Another Hospital: Variable Priority	41
Disease Specific Indications for ICU Admission	41
Cardiovascular System	41
Pulmonary System	42
Neurological Disorders	42
Drug Ingestion and Drug Overdose	42
Gastrointestinal Disorders	43
Endocrine	43
Renal Disorders	43
Postoperative Care	44
Miscellaneous	44
Physiologic Indication for ICU Admission	44
Discharge Criteria	44
Reference	45
8 Chronic Critical Illness and the Long Term Sequela of Critical Care	47
Neuromuscular Abnormalities	49
Critical Illness Polyneuropathy	49
Critical Illness Myopathy (See also Chap. 32 on Nutrition)	49
Brain Dysfunction	51
"Prevention" of CCI	51

Management of CCI.....	52
Testing.....	52
General Management.....	53
Stress Hyperglycemia.....	53
Metabolic Bone Disease.....	53
Anabolic Steroids.....	54
Exercise Program.....	54
References.....	54
9 Fluid Responsiveness and Fluid Resuscitation.....	57
Echocardiographic Assessment of Fluid Responsiveness.....	66
Static Echocardiographic Parameters.....	66
Dynamic Echocardiographic Parameters.....	66
Passive Leg Raising (PLR).....	67
The Fluid Challenge.....	69
Fluid Boluses in Volume Responsive Patients.....	71
What Type of Fluid?.....	72
Lactated Ringer's (Hartmann's Solution) vs. 0.9 % NaCl (Ab-Normal Saline).....	72
Complications Associated with 0.9 % NaCl vs. Lactate Ringers Solution.....	73
Renal Failure.....	73
Hyperchloremic Metabolic Acidosis and DEATH.....	73
Lactate Generates HCO_3^-	73
Ringer's Lactate and Kidney Disease.....	74
Ringers Lactate and Liver Disease.....	75
Coagulopathy.....	75
Lactate as a Metabolic Fuel.....	75
Albumin.....	76
Hetastarches (HES).....	77
So, Which Fluid?.....	78
Resuscitation in Specific Disease States.....	78
Hemorrhage.....	78
Traumatic Brain Injury.....	79
Dehydration.....	79
Sepsis (and SIRS).....	80
Burns.....	80
Management of Oliguria.....	80
Management of Volume Overload/Acute Pulmonary Edema.....	81
References.....	81
10 Assessment of Cardiac Function and Cardiac Output.....	89
Echocardiographic Assessment of Cardiac Function.....	89
Methods of Measuring Cardiac Output.....	90
Pulmonary Artery Catheter.....	90
Transpulmonary Thermodilution.....	91

Pulse Contour Analysis	92
Esophageal Doppler	93
USCOM	93
Bioreactance	94
Utility of Cardiac Output monitoring	94
Determining Fluid and Inotrope Responsiveness	94
Driving up CI to Supranormal Values	94
References	95
11 Peri-operative Fluid Optimization	99
References	104
12 Sepsis	107
Bacteriology and Sites of Infection	108
Pathophysiology of Sepsis	109
Septic “Cardiomyopathy”	109
Complications Associated with Sepsis	111
Clinical Features and Diagnosis of Sepsis	112
Organ Dysfunction in Severe Sepsis/Septic Shock	112
Management of Sepsis	115
Antibiotic Therapy	118
Fluid Therapy (See also Chap. 9)	119
Vasopressors and Inotropic Agents	124
B-Blockers and Phenylephrine in Septic Shock	128
Resuscitation End-Points	129
The Dangers of a HIGH CVP	130
Does Tissue Hypoxia and Mitochondrial Dysfunction Exist in Sepsis?	133
Case Example	136
References	137
13 The Stress Response, Stress Hyperglycemia and Stress Hyperlactemia	149
The Stress Response	149
Cardiovascular Effects of the Stress Response	152
Immune Effects of the Stress Response	152
Metabolic Effects of the Stress Response	153
Stress Hyperglycemia	153
Treatment of “Stress Hyperglycemia”	155
So What to Do!	157
How to Achieve These Goals?	157
Glucose Control and Steroids	158
Stress Hyperlactemia	158
Lactate Metabolism	159
Lactate as a Marker of Illness Severity	160
Lactate as a Marker of Metabolic Stress	161

Lactate as a Metabolic Fuel	162
Heart Metabolism and Lactate	163
Brain Metabolism and Lactate	163
References	164
14 Understanding the Vital Signs: BP, HR, RR, TEMP, SaO₂, ... and SV	169
Blood Pressure	169
The Brain-Heart Distance and the Giraffe Theory of Blood Pressure	
Determination in Humans	170
What's a Normal Blood Pressure?	171
BP Thresholds for the Intensivist/Anesthesiologist	172
Non-Invasive Blood Pressure (NIBP) vs Arterial Line Blood Pressure (IAP) and Systolic Blood Pressure (SBP) vs Mean Arterial Pressure (MAP)	172
Central vs Peripheral Blood Pressure Measurement	173
Blood Pressure Autoregulation	174
MAP, Organ Failure and Death	175
Circulatory Shock	176
Pulse Rate	177
Respiratory Rate (& Pattern)	178
Temperature	179
Pulse Oximetry	179
Too Much Oxygen Kills	184
Analysis of the Oximetric Waveform	188
Stroke Volume: The 6th Vital Sign	189
Putting the Vital Signs Together	190
Early Warning Scoring Systems and Rapid Response Teams	191
References	192
15 Management of Pain, Agitation and Delirium	197
Assessing the Level of Pain and Sedation	200
The Ramsey Sedation Scale	201
The Richmond Agitation-Sedation Scale (RASS)	201
Sedation Vacations	202
Non-pharmacologic Interventions	202
Delirium	202
Sedative and Analgesics Agents	205
Lorazepam	205
Midazolam	206
Propofol	206
Dexmedetomidine	207
Haloperidol	208
Fentanyl	208
Morphine	208
Meperidine	208

Neuromuscular Blockade.....	209
Neuromuscular Blocking Agents	209
References.....	210
16 Hospital Acquired Infections and Their Prevention.....	213
Colonization with Multidrug Resistant Organisms.....	215
Handwashing and Infection Control Measures.....	216
Handwashing.....	216
Chlorhexidine Bathing	216
Gloves and Gowns and Healthcare Provider Apparel.....	217
Universal Screening for MDR's and "Protective Isolation"	217
Oropharyngeal and Gastrointestinal Decolonization	218
Private Rooms and Environmental Control	219
Central Line Associated Blood Stream Infection.....	220
Management of CLABSI's	224
Antibiotics Lock Therapy	225
Prevention of CLABSI.....	225
Catheter Associated Urinary Tract Infection.....	227
Ventilator Associated Pneumonia	229
Pathogenesis of VAP	230
Diagnosis of VAP	232
Treatment	234
General Concepts for the Antimicrobial Treatment of VAP	234
Empiric Antibiotic Choices.....	235
"Specific" Interventions for Prevention of VAP.....	235
<i>Clostridium difficile</i> Infection	239
Laboratory Diagnosis.....	241
Sigmoidoscopy.....	242
Treatment	243
Fidaxomicin	244
Adjunctive Treatment Options	244
Probiotics	245
Surgical Intervention.....	245
Nosocomial Rhinosinusitis	246
References.....	248
Part II Pulmonary	
17 The Bacterial Pneumonias: A New Treatment Paradigm.....	261
Unified Treatment Algorithm.....	263
No Risk Factors for a CAP-DRP	263
Risk Factors for CAP-DRPs	264
Influenza (Co-Existent or Influenza Pneumonia).....	264
Diagnostic Testing of Hospitalized Patients with Pneumonia	265
Non-Infectious Diseases Masquerading as Pneumonia	265
Special Considerations.....	266
Severe CAP with no MDR Risk Factors.....	266

Community-Acquired MRSA Pneumonia (CA-MRSA).....	266
Aspiration Pneumonia.....	267
Nursing Home-Acquired Pneumonia.....	269
Persistent Temperature/Failure to Respond to Rx.....	269
Unusual Pathogens.....	270
Complicated Pleural Effusion/Empyema.....	271
References.....	271
18 Fever.....	275
Common Misconception and Fables.....	275
Pathogenesis of Fever.....	276
Treatment of Fever.....	276
Causes of Fever in the ICU.....	278
Infectious Causes of Fever in the ICU.....	279
Non-Infections Causes of Fever in the ICU.....	279
Non-Infectious Causes of Fever.....	279
An Approach to the Febrile ICU Patient.....	286
Clinical Pearls.....	288
References.....	288
19 Mechanical Ventilation 101.....	291
Alveolar Overdistension Damages Normal Lungs.....	293
Ventilator Variables and Modes of Ventilation.....	293
Ventilator Variables (See Table 19.1).....	297
Common Modes of Mechanical Ventilation.....	299
Positive End-Expiratory Pressure (PEEP).....	303
Auto-PEEP.....	305
Monitoring Patients Undergoing Mechanical Ventilation.....	306
Sudden Increase in Airway Pressure and/or Fall in Arterial Saturation.....	307
When to Perform a Tracheostomy.....	307
Timing of Tracheostomy in the Critically Ill.....	308
References.....	308
20 Non-invasive Ventilation.....	311
Set Up.....	312
Initial Settings.....	312
Indications of NIV.....	313
COPD Exacerbations.....	313
Acute Cardiogenic Pulmonary Edema.....	313
Facilitating Extubation in COPD Patients.....	313
Immunocompromised Patients.....	314
Post-operative Patients.....	314
When to Use NIV.....	315
Hypercapnic Respiratory Failure.....	315
Hypoxemic Respiratory Failure.....	315

Contraindications to NIPPV	315
Success and Failure Criteria for NIPPV	316
References.....	316
21 Liberation (Weaning from Mechanical Ventilation).....	319
General Concepts.....	319
Effect of Liberation on Oxygen Consumption and Cardiac Function ..	320
Fluid Overload and Liberation Failure.....	320
Vasopressors and Inotropic Agents and Weaning	321
<i>Mechanical Ventilation</i> Liberation Process	322
“Readiness” Testing	322
Spontaneous Breathing Trials	323
Causes of Liberation Failure.....	324
Early Extubation Followed by NIV in COPD	324
NIV for Persistent Liberation Failure	324
Extubation Failure.....	325
Patients at High Risk of Extubation Failure.....	325
The Cuff Leak Test.....	326
Corticosteroids for the Prevention of Post-extubation Stridor.....	326
References.....	326
22 Arterial Blood Gas Analysis.....	329
Indications for ABG Sampling.....	329
ABG Sampling.....	330
ABG Analysis	331
Alveolar Ventilation	332
Oxygenation.....	332
Acid-Base Balance.....	334
A Step Wise Approach to Acid-Base Disorders.....	335
Common Acid Base Disturbances in the ICU.....	338
Metabolic Acidosis.....	338
Metabolic Alkalosis	341
Venous Blood Gas Analysis (VBGs)	342
Mixed Venous/Central Venous Oxygen Saturation	343
References.....	344
23 ARDS.....	349
Definition, Causes and Assessment of Severity	349
Definition of ALI According the American European Consensus	349
Acute Lung Injury (ALI)	349
Acute Respiratory Distress Syndrome (ARDS).....	350
Pathophysiological Definition of ARDS.....	350
Causes of ALI	351
Management of the Acute Phase of ARDS	351
Ventilatory Strategy	352
Pressure Controlled Ventilation.....	355

Airway Pressure Release Ventilation	357
Permissive Hypercapnia.....	359
Best PEEP	359
Recruitment Maneuvers	361
Non-Ventilatory Adjuncts to Gas Exchange	361
Prone Positioning	361
Neuromuscular Blocking Agents	362
ECMO	362
Corticosteroids	363
Inhaled Nitric Oxide	365
Nebulized Prostacyclin	365
β_2 -Adrenergic Receptor Agonists.....	365
Surfactant	365
Omega-3 Enteral Nutrition.....	366
“Our” Approach to Refractory Hypoxemia	366
References.....	367
24 COPD Exacerbation	373
Common Precipitating Events	374
Indications for Hospitalization.....	375
Indications for ICU Admission	375
Treatment	375
Indications for NPPV	377
Indications for Endotracheal Intubation.....	377
Mechanical Ventilation in COPD.....	377
Suggested Initial Settings.....	378
References.....	378
25 Acute Severe Asthma	381
Indications for Admission to the ICU	382
Initial Treatment.....	382
Other Therapeutic Options.....	383
Complications of Acute Asthma	384
Noninvasive Positive-Pressure Ventilation in Status Asthmaticus	384
Indications for Intubation.....	385
Sedation Post-intubation	386
Mechanical Ventilation.....	386
Initial Ventilator Settings.....	387
References.....	388
26 Pleural Effusions and Atelectasis	391
Pleural Effusions	391
Pathophysiology.....	391
Drainage of Pleural Effusion.....	392
Hepatic Hydrothorax.....	393

Alelectasis	393
Respiratory Therapy	394
Mucolytics.....	394
Bronchoscopy	395
Bilevel/APRV	395
References.....	396
27 Venous Thromboembolic Disease: DVT and PE.....	399
Pregnancy, Venous Thromboembolism and Thrombophilias.....	399
Site of Venous Thrombosis	400
The Veins of the Lower Limb	401
Suggested DVT Prophylaxis Protocols.....	405
Diagnosis of DVT	405
Distal Lower Extremity DVT.....	406
Upper Extremity DVT	406
Superficial Phlebitis	407
Pulmonary Embolism.....	408
Diagnosis of Pulmonary Embolism	408
Treatment of Thromboembolic Disease.....	411
Thrombolytic Therapy	413
Catheter Directed Clot Fragmentation and Aspiration.....	418
Inhaled Nitric Oxide	418
Vena Caval Interruption	419
“Absolute Contraindications” for Anticoagulation with Heparin	419
References.....	419
Part III Cardiac	
28 Hypertensive Crises	429
Definitions.....	429
Pathophysiology	430
Clinical Presentation	431
Initial Evaluation.....	432
Initial Management of Blood Pressure	433
Resident (or Hospitalist) Called to the Floor for High	
Blood Pressure: What to Do?.....	434
Drugs to AVOID.....	436
Recommended Antihypertensive Agents	437
Acute Postoperative Hypertension	439
Pre-operative Hypertension.....	440
Posterior Reversible Encephalopathy Syndrome (PRES).....	441
Pregnancy-Induced PRES	441
Drugs Associated with PRES.....	442
References.....	442

29 Acute Decompensated Cardiac Failure	445
Confirm the Diagnosis of Cardiac Failure	446
Evaluation of the Patient with Cardiac Failure	447
B-Type Natriuretic Peptides.....	447
Echocardiography	448
Laboratory Testing	448
Hemodynamic Monitoring.....	448
Precipitating Factors	449
Treatment	449
Acute Phase of Treatment	449
Treatment of ADHF: Summary.....	456
Long-Term Management	456
Systolic Heart Failure	457
Management of Patients with Heart Failure with Preserved Ejection Fraction (HFpEF).....	461
Takotsubo Cardiomyopathy	462
Stressors Reported to Trigger Takotsubo Cardiomyopathy.....	462
Mayo Clinic Criteria for Takotsubo Cardiomyopathy	464
References.....	465
30 Acute Coronary Syndromes	471
Unstable Angina/NSTEMI.....	471
Canadian Cardiovascular Classification of Angina.....	472
Types of Presentations of Unstable Angina	472
Differential Diagnosis	472
Electrocardiography	472
Tropinins	473
Management of UA/NSTEMI.....	473
Risk Stratification.....	473
Thrombolysis in Myocardial Infarction (TIMI) Risk Score.....	473
Global Registry of Acute Coronary Events (GRACE) Risk Model	474
Treatment Approach for UA and NSTEMI (PER AHA Guidelines)	474
Class I Recommendations.....	474
Class II Recommendations	475
Treatment Approach to STEMI (PER AHA Guidelines).....	475
Class I Recommendations.....	475
Class II Recommendations	476
Complications Following STEMI.....	477
Recurrent Chest Pain Post-AMI.....	477
Mitral Regurgitation.....	477

Left Ventricular Failure and Low Output States	478
Right Ventricular Infarction	478
Atrial Fibrillation	478
References.....	479
31 Arrhythmias	481
Arrhythmias and Electrolyte Disturbances	481
Acute Atrial Fibrillation/Flutter	482
Urgent Cardioversion.....	483
Rate Control	483
Pharmacologic Cardioversion.....	484
Anticoagulation.....	484
Multifocal Atrial Tachycardia (MAT).....	485
Paroxysmal Supraventricular Tachycardia (PSVT)	485
Management.....	486
SVT Mediated by Accessory Pathways	486
Sinus Bradycardia	487
Sick-Sinus Syndrome.....	487
Accelerated Idioventricular Rhythm.....	487
Ventricular Premature Complexes and Bigeminy	487
Nonsustained Ventricular Tachycardia.....	488
Sustained Ventricular Tachycardia	488
Polymorphic Ventricular Tachycardia (Torsades De Pointes).....	489
Management.....	489
References.....	490
Part IV Gastrointestinal	
32 Nutrition in the ICU: It's Whey Cool.....	493
Myths of Nutritional Support.....	494
Important Points to Digest	495
How Many Calories and How Much Protein to Give?	498
Muscle Wasting in Critical Illness	499
Factors That Activate Muscle Synthesis by the mTOR Pathway.....	502
Bolus vs. Continuous Feeding	504
So! What is the Best Way to Feed Critically Ill Patients?.....	506
The Obese Patient	507
The Refeeding Syndrome	507
References.....	508
33 Stress Ulcer Prophylaxis.....	513
Does SUP Reduce GI Bleeding?.....	514
Enteral Nutrition and Stress-ulcer Prophylaxis.....	515
Complications Associated with Acid Suppressive Therapy.....	516
So! What to Do?.....	517
Complications Associated with Specific Drugs	517

H2 Receptor Antagonists (H2RA)	517
Proton Pump Inhibitors (PPIs)	518
Sucralfate	518
References	519
34 Acute and Chronic Liver Disease	523
Chronic Liver Failure	523
Causes of Cirrhosis	524
Metabolic/Hematologic Derangements in Cirrhosis	525
Spontaneous Bacterial Peritonitis	525
Hepatic Encephalopathy	527
Grades of Hepatic Encephalopathy	528
Hepatorenal Syndrome	529
Hepatorenal Syndrome: Diagnostic Criteria	530
Diagnostic Approach	530
Treatment of HRS	531
Hepato-adrenal Syndrome	532
Pulmonary Consequences of Portal Hypertension	532
Infection and Cirrhosis	532
Supportive Care of the Hospitalized Cirrhotic	533
The Coagulopathy of Chronic Liver Disease	534
Portal Vein Thrombosis	535
Acute-on-chronic Liver Failure	537
Alcoholic Hepatitis	538
Differential Diagnosis	539
Management	539
Fulminant Hepatic Failure	540
Causes of Fulminant Hepatic Failure	541
Workup of Patients Presenting with FHF	541
Cerebral Edema in FHF	542
Management of Increased ICP	543
Supportive Measures	545
Indications for Liver Transplantation	545
Kings Criteria	546
References	546
35 GI Bleeding	551
Initial Assessment	551
Initial Resuscitation	553
Triage of Patients. Who to Admit to the ICU?	555
Upper GI Bleeding	555
The Major Causes of UGIB Include	556
Further Management of Upper GI Bleeding (See Fig. 35.1)	556
Further Management of Bleeding Peptic Ulcers	557
Recurrent Hemorrhage	559

Further Management of Esophageal Varices.....	559
Management of Patients with Lower GI Bleeding.....	560
References.....	562
36 Pancreatitis	565
Diagnosis.....	566
Risk Stratification.....	567
Complications	568
Management.....	569
References.....	571
37 Diarrhea & Constipation.....	575
Diarrhea.....	575
Infectious Diarrhea.....	575
“Non-Infectious” Diarrhea.....	576
Antibiotic Associated Diarrhea (AAD).....	576
Enteral Feeding-Associated Diarrhoea	576
Management of “Non-Infectious” Diarrhoea.....	576
The Use of Probiotics and Prebiotics.....	577
Constipation	579
References.....	580
Part V Miscellaneous	
38 Transfusion of Blood and Blood Products	585
Red Blood Cell Transfusions	585
Why Transfuse?	586
Risks Associated with Blood Transfusion (See Fig. 38.1).....	586
Risks Associated with Blood Transfusion.....	587
Transfusion-Associated Immunomodulation	588
“Age” of Transfused Red Blood Cells	590
Tolerance to Anemia	596
Weighing the Risks and Benefits of Blood Transfusion	596
So, When Should Patients’ Be Transfused?	597
Coagulation Disorders in the ICU.....	598
Fresh Frozen Plasma	600
FFP Prior to Invasive Bedside Procedures or Surgery	601
Paracentesis.....	604
Management of Non-therapeutic INRs With or Without Bleeding (Due to Coumadin Therapy)	604
Platelet Transfusion.....	606
Heparin Associated Thrombocytopenia	610
Thrombotic Thrombocytopenic Purpura (TTP).....	612
Cryprecipitate.....	614
References.....	614

39 Adrenal Insufficiency	621
Causes of Adrenal Insufficient/Circi	622
Clinical Features of Adrenal Insufficiency/Circi	623
Diagnosis of Adrenal Insufficiency/Circi	624
Factors Affecting the Response to Corticosteroid Treatment	625
The Immune Status of the Host	625
Timing of Corticosteroids	626
Dose and Dosing Strategy	626
Acute Rebound After Discontinuation of Corticosteroids	627
Genetic Polymorphisms	627
Abnormalities of the Glucocorticoid Receptor	628
Treatment of Adrenal Insufficiency/CIRCI	628
Who to Treat with Steroids?	628
Adverse Effects of Corticosteroids	630
References	631
40 Electrolyte Disturbances	635
Sodium and Water	635
Rules of the Game	635
Hyponatremia	635
Hypernatremia	640
Hypokalemia	641
Hyperkalemia	641
Hypophosphatemia	642
Management	643
Hypomagnesemia	643
Management of Hypomagnesemia	644
Disorders of Calcium Homeostasis	645
Hypocalcemia	646
Should Hypocalcemia Be Corrected in Critically Ill Patients?	647
Treatment	647
Hypercalcemia	648
Treatment	649
Second Line	649
Additional Therapies	650
References	650
41 Acute Kidney Injury	653
Pre-Renal Azotemia	654
Contrast Agents and the Kidney	655
Prevention of Contrast Induced AKI	655
“Common” Nephrotoxic Agents	656
Management of Established Acute Renal Failure	657
When to Initiate Renal Replacement Therapy (RRT)	657

Mode of Renal Replacement Therapy	658
Advantages of CRRT Therapy Include	658
Dosing of RRT	659
Summary of Recommendations for RRT in Patients with AKI	659
Rhabdomyolysis	659
Epidemiology	660
Etiology	660
Pathophysiology	663
Mechanisms of Acute Renal Failure in Rhabdomyolysis Patients	663
Clinical Manifestations	663
Laboratory Findings	664
Management	664
Dialysis	665
References	666
42 Acute Ischemic Stroke	669
Stroke ICU's, Medical ICU's or Stroke Units	670
Profiles Predictive of Futility After Devastating Stroke	670
Acute Ischemic Stroke (AIS)	671
Imaging	671
Thrombolytic Therapy	672
Treatment of Acute Ischemic Stroke With Intravenous rtPA	674
Endovascular Interventions	675
Antiplatelet Therapy and Anti-Coagulation	676
Anticoagulation in Cardio-Embolic Stroke	676
Raised ICP and Decompressive Surgery	677
Treatment of Hyperglycemia	678
Treatment of Fever	678
Treatment of Post Stroke Hypertension	678
Supportive Medical Therapy	680
References	681
43 Intracerebral and Subarachnoid Hemorrhage	685
Intracerebral Hemorrhage	685
Medical Management	687
Blood Pressure Control	689
Surgical Interventions	690
Subarachnoid Hemorrhage	692
Diagnosis and Evaluation	693
Initial Management	693
Specific Therapeutic Issues	698
Antifibrinolytic Therapy	698
Surgical and Endovascular Methods of Treatment	698
Management of Cerebral Vasospasm	698
Transpulmonary Thermodilation (TPTD) Hemodynamic Assessment	701

Subdural Hematoma.....	702
Epidural Hematoma	703
Increased Intracranial Pressure (ICP)	703
Measurement of ICP	704
Indications for ICP Monitoring.....	704
Management of Raised ICP	705
References.....	708
44 Seizures & Status Epilepticus	717
Seizures in the ICU	717
Seizures Occurring as a Complication of Critical Illness	718
Seizures from Primary Neurological Disease	719
Management.....	719
Seizure Therapy	719
Status Epilepticus.....	720
Etiology.....	721
Common Causes of Status Epilepticus Include	721
Pathophysiology.....	722
Complications of Generalized Status Epilepticus.....	722
Diagnosis.....	722
Treatment	723
General Measures.....	723
Pharmacotherapy.....	724
Management of Refractory Status Epilepticus	726
The Management of Nonconvulsive Status Epilepticus	727
Prevention of Seizure Recurrence Once Status Epilepticus is Terminated.....	728
References.....	728
45 Toxicology	731
General Measures.....	731
Technique for Performing Gastric Lavage.....	732
Activated Charcoal.....	732
Hemodialysis/Hemoperfusion.....	733
Common Agents Responsible for	734
Common Intoxications.....	735
Acetaminophen	735
Salicylates	738
Tricyclic Antidepressants	738
Acute Ethanol Intoxication	739
Ethylene Glycol and Methanol Poisoning	740
Ethylene Glycol	740
Methanol	741
Isopropyl Alcohol.....	742
Digitalis.....	743
Phenytoin	743
Lithium.....	744

Opiates	745
Cocaine	745
Carbon Monoxide Poisoning	748
References	750
46 Alcohol Withdrawal Syndrome	751
The Clinical Institute Withdrawal Assessment Scale for Alcohol (CIWA-Ar)	753
Differential Diagnosis	753
Treatment	754
Other Treatment Considerations	755
Prevention of Post-operative DT's	756
References	756
47 Pregnancy Related Disorders	759
Obstetrical Hemorrhage	760
Antepartum Hemorrhage	760
Postpartum Hemorrhage	760
Management	760
Hypertension	761
Pre-eclampsia	761
Diagnosis of Pre-eclampsia	762
HELLP Syndrome	764
Posterior Reversible Encephalopathy Syndrome (PRES)	765
Treatment of Pre-eclampsia	765
Anti-hypertensive Agents for the Treatment of Pre-eclampsia	766
Corticosteroids and Plasmapheresis as Adjunctive Treatment of HELLP	767
Acute Fatty Liver of Pregnancy	768
Amniotic Fluid Embolus Syndrome	768
Sepsis in Pregnancy	768
Respiratory Failure in Pregnancy	769
References	770
48 The Geriatric ICU Patient	773
The Physiology of Aging	773
Cardiovascular Changes	774
Changes in Respiratory Function	775
Changes in Renal Function	775
Immune System Changes	776
Body Composition and Muscle Mass	776
The Outcome of Elderly Patients Admitted to the ICU	776
Trauma and the Elderly Patient	778
Surgery and the Elderly	778
Delirium in the Elderly	779
Drug Dosing and Polypharmacy in the Elderly	780

American Geriatric Society Beers Criteria	781
Drugs to Avoid in the Elderly	781
References	782
49 Obesity in the ICU	787
Effect of Obesity on Critical Care Outcomes	787
Respiratory Effects of Obesity	788
Ideal Body Weight.....	789
Cardiovascular Effects of Obesity	789
Hepatic and Renal Effects of Obesity	790
Drug Dosing in Obese Patients	790
Nutritional Requirements.....	790
Gaining Vascular Access	791
Radiological Procedures	791
Malignant Obesity Hypoventilation Syndrome (MOHS)	791
Major Criteria.....	792
Minor Criteria	792
Treatment of MOHS	792
References	793
50 Radiology	797
The Chest Radiograph.....	797
Position of Tubes and Catheters.....	798
Lung Parenchyma, Pleura and Mediastinum	798
Plain Abdominal Radiography	801
Computed Tomography (CT).....	801
Indium Labeled Leukocyte Scans	802
References	803
51 End-of-Life Issues	805
Palliative Care	806
“Principles” of Palliative Care	807
References	809
52 Words of Wisdom.....	811
References	812
Index.....	813

Evidence-Based Critical Care

Marik, P.E.

2015, XXXIII, 835 p. 83 illus., 46 illus. in color., Softcover

ISBN: 978-3-319-11019-6